• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Treatment choices aid cancer patients, doctors

Arguably, the biggest advance in skin cancer therapy is the development of topical medications.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
Related Content
Update: FDA Extends Review of Ruxolitinib Cream for Pediatric AD
June 20th 2025

Update: FDA Extends Review of Ruxolitinib Cream for Pediatric AD

Derm Dispatch: Advocating for Skin and Nail Health to Spread Melanoma Awareness
May 23rd 2025

Derm Dispatch: Advocating for Skin and Nail Health to Spread Melanoma Awareness

Nail Trends That Challenge Clinical Diagnosis
June 20th 2025

Nail Trends That Challenge Clinical Diagnosis

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor
May 20th 2025

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor

FDA Approves Dupilumab, First and Only Targeted Medicine for Bullous Pemphigoid
June 20th 2025

FDA Approves Dupilumab, First and Only Targeted Medicine for Bullous Pemphigoid

Q&A Part 1: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD
June 20th 2025

Q&A Part 1: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD

© 2025 MJH Life Sciences

All rights reserved.